Literature DB >> 22095787

P2Y6 receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells.

Djordje M Grbic1, Émilie Degagné, Jean-François Larrivée, Maude S Bilodeau, Valérie Vinette, Guillaume Arguin, Jana Stankova, Fernand-Pierre Gendron.   

Abstract

BACKGROUND: Inflammatory bowel diseases are characterized by the presence of CXCL8 at the site of lesions resulting in neutrophil recruitment and loss of tissue functions. We report that P2Y(6) receptor activation stimulates CXCL8 expression and release by intestinal epithelial cells (IECs). In this context, we investigated if uridine 5'-diphosphate (UDP) enemas stimulate neutrophil recruitment to the mucosa of mice suffering from colitis-like disease and we characterized the signaling events linking P2Y(6) to CXCL8 expression in IEC.
METHODS: Neutrophil recruitment was monitored by immunofluorescence and FACS analysis. Expression of Cxcl1, a mouse functional homolog of CXCL8, was determined by quantitative real-time polymerase chain reaction (qPCR). Pharmacological inhibitors and interfering RNAs were used to characterize the signaling pathway. The outcomes of these treatments on protein phosphorylation and on CXCL8 expression were characterized by western blots, qPCR, luciferase, and chromatin immunoprecipitation (ChIP) assays.
RESULTS: Mutation of the AP-1 site in the CXCL8 core promoter abolished the UDP-stimulating effect. The c-fos/c-jun dimer was identified as the AP-1 complex regulating CXCL8 in response to UDP stimulation. Regulation of CXCL8 expression by P2Y(6) required PKCδ activation upstream of the signaling pathway composed of MEK1/2-ERK1/2 and c-fos. UDP administration to mice suffering from colitis-like disease increased the number of neutrophil infiltrating the mucosa, correlating with Cxcl1 increased expression in IEC and the severity of inflammation.
CONCLUSIONS: This study not only describes the P2Y(6) signaling mechanism regulating CXCL8 expression in IEC, but it also illustrates the potential of targeting P2Y(6) to reduce intestinal inflammation.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095787     DOI: 10.1002/ibd.21931

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  21 in total

Review 1.  Extracellular ATP and other nucleotides-ubiquitous triggers of intercellular messenger release.

Authors:  Herbert Zimmermann
Journal:  Purinergic Signal       Date:  2015-11-06       Impact factor: 3.765

Review 2.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 4.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

5.  Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y6 Receptor Agonists.

Authors:  Kiran S Toti; Shanu Jain; Antonella Ciancetta; Ramachandran Balasubramanian; Saibal Chakraborty; Ryan Surujdin; Zhen-Dan Shi; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-09-06       Impact factor: 3.597

6.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

7.  4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor.

Authors:  P Suresh Jayasekara; Matthew O Barrett; Christopher B Ball; Kyle A Brown; Eszter Kozma; Stefano Costanzi; Lucia Squarcialupi; Ramachandran Balasubramanian; Hiroshi Maruoka; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2013-05-30       Impact factor: 3.597

Review 8.  The roles of purinergic signaling during gastrointestinal inflammation.

Authors:  Jane A Roberts; Mark K Lukewich; Keith A Sharkey; John B Furness; Gary M Mawe; Alan E Lomax
Journal:  Curr Opin Pharmacol       Date:  2012-10-11       Impact factor: 5.547

Review 9.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

10.  Suramin protects from cisplatin-induced acute kidney injury.

Authors:  Tess V Dupre; Mark A Doll; Parag P Shah; Cierra N Sharp; Alex Kiefer; Michael T Scherzer; Kumar Saurabh; Doug Saforo; Deanna Siow; Lavona Casson; Gavin E Arteel; Alfred Bennett Jenson; Judit Megyesi; Rick G Schnellmann; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.